

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Saliva or nasopharyngeal swabs for SARS-CoV-2 screening, renin-angiotensin-system inhibitors, social pharmacology

#### Peer reviewed journals featured:

- A rapid review comparing saliva and nasopharyngeal swabs for SARS-CoV-2 RT-PCR screening [here](#)
- A randomised controlled trial on discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 [here](#) and associated commentary [here](#)
- Observational studies on:
  - Injection fears and COVID-19 vaccine hesitancy [here](#)
  - Drug-drug interactions between pharmacotherapy and concomitant medication in COVID-19 patients [here](#)
  - ‘Adverse events of special interest’ for COVID-19 vaccines in eight countries [here](#)
  - Breakthrough rates of variants of concern in Pfizer vaccinated individuals [here](#)
  - Immunogenicity and safety of the Pfizer vaccine in patients with autoimmune inflammatory rheumatic disease and in the general population [here](#)
  - SARS-CoV-2 infection and immune-mediated myopathy in deceased patients [here](#)
  - Children and youth hospitalised with COVID-19 in six countries [here](#)
  - Trends in venous thromboembolism anticoagulation in hospitalised COVID-19 patients [here](#) and associated commentary [here](#)
- A modelling study on meteorological factors in SARS-CoV-2 transmission in the US [here](#)
- A conference report on evaluating COVID-19 vaccine effectiveness, post-introduction [here](#)
- Editorials on:
  - Vaccinating children against SARS-CoV-2 [here](#)
  - Addressing the vaccination gap in aged care [here](#)
  - The implications of SARS-CoV-2 viral load in children [here](#)
- Case reports on:
  - Treatment of spleno-porto-mesenteric vein thrombosis after AstraZeneca vaccine [here](#)
  - Guillain-Barré syndrome following AstraZeneca vaccine [here](#) and [here](#)
  - Bilateral chilblain-like lesions of the toes in adolescents [here](#)
- Commentaries on:
  - COVID-19 vaccines from a social pharmacology perspective [here](#)
  - Evaluation and care of patients with persistent symptoms after acute SARS-CoV-2 [here](#)
  - Self-care, social norms and anomie during COVID-19 in the UK [here](#)

## Letters and correspondence discussed:

- Organ transplantation outcome in recipients from a deceased donor with SARS-CoV-2 vaccine-induced thrombotic thrombocytopenia [here](#)
- SARS-CoV-2 Delta variants of concerns in Scotland [here](#)
- Bell's palsy and SARS-CoV-2 vaccines [here](#) and authors' reply [here](#)
- The first manifestation of multiple sclerosis after immunisation with Pfizer vaccine [here](#)
- Immunogenicity and safety of mRNA vaccines in patients with chronic inflammatory conditions [here](#)
- Importance of the second dose of the COVID-19 mRNA vaccine [here](#) and [here](#)
- Estimation of excess mortality rates among US assisted living residents during COVID-19 [here](#)
- Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients [here](#)

## Guidance and reports

- The World Health Organization updated its COVID-19 vaccine tracker [here](#)

## News and blogs

- A podcast on counting the cost of disability caused by COVID-19 [here](#)
- Using 'big data' to disentangle aging and COVID-19 [here](#)
- A long-term perspective on immunity to COVID-19 [here](#)
- The US regulator raises "significant concerns" over safety of rapid lateral flow tests [here](#)
- COVID-19 Delta variant and mitigation in schools in the UK [here](#)

[Click here](#) to subscribe to the daily evidence digest.

### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(PASC\)](#).